GSK (LON:GSK) Issues Earnings Results

GSK (LON:GSK - Get Free Report) posted its earnings results on Wednesday. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a return on equity of 33.30% and a net margin of 12.83%.

GSK Stock Down 2.5 %

Shares of GSK stock traded down GBX 36.50 ($0.45) during trading on Friday, hitting GBX 1,443 ($17.90). The company's stock had a trading volume of 13,487,003 shares, compared to its average volume of 29,882,320. GSK has a 52 week low of GBX 1,282.50 ($15.91) and a 52 week high of GBX 1,823.50 ($22.62). The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. The company has a fifty day simple moving average of GBX 1,358.76 and a two-hundred day simple moving average of GBX 1,456.33. The company has a market capitalization of £58.87 billion, a PE ratio of 1,276.99, a P/E/G ratio of 1.24 and a beta of 0.31.

Insiders Place Their Bets

In other news, insider Jonathan Symonds purchased 1,500 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were bought at an average price of GBX 1,315 ($16.31) per share, for a total transaction of £19,725 ($24,466.63). Corporate insiders own 1.61% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on GSK shares. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank reduced their price target on shares of GSK from GBX 1,820 ($22.58) to GBX 1,600 ($19.85) and set a "buy" rating on the stock in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, GSK presently has a consensus rating of "Moderate Buy" and a consensus price target of GBX 1,805.83 ($22.40).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.